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Abstract
Most studies evaluating the effect of Xpert MTB/RIF testingBackground: 
for tuberculosis (TB) concluded that it did not reduce overall mortality
compared to usual care. We conducted a systematic review to assess
whether key study design and execution features contributed to earlier
identification of patients with TB and decreased pre-treatment loss to
follow-up, thereby reducing the potential impact of Xpert MTB/RIF testing.
We searched the Cochrane Central Register of Controlled TrialsMethods: 
(CENTRAL), MEDLINE, and Scopus for literature published from 1
January 2009 to February 2019. We included all primary intervention
studies that had evaluated the effect of Xpert MTB/RIF on mortality
compared to usual care in participants with presumptive pulmonary TB. We
critically reviewed features of included studies across: Study setting and
context, Study population, Participant recruitment and enrolment, Study
procedures, and Study follow-up.
We included seven randomised and one non-randomised study. Results: 
All included studies demonstrated relative reductions in overall mortality in
the Xpert MTB/RIF arm ranging from 6% to 40%. However, mortality
reduction was reported to be statistically significant in two studies. Study
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 reduction was reported to be statistically significant in two studies. Study
features that could explain the lack of observed effect on mortality included:
the higher quality of care at study sites; inclusion of patients with a higher
pre-test probability of TB leading to higher than expected empirical rates;
performance of additional diagnostic testing not done in usual care leading
to increased TB diagnosis or empiric treatment initiation; the recruitment of
participants likely to return for follow-up; and involvement of study staff in
ensuring adherence with care and follow-up.
Most studies of Xpert MTB/RIF were designed and conductedConclusion: 
in a manner that resulted in more patients being diagnosed and treated for
TB, minimising the potential difference in mortality Xpert MTB/RIF testing
could have achieved compared to usual care.
Keywords
Tuberculosis diagnosis, methodology, Diagnostic trials, Impact studies
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Introduction
Tuberculosis (TB) is the leading cause of mortality from an 
infectious disease globally. The 2018 World Health Organiza-
tion (WHO) TB report estimates that there were 10 million 
incident TB cases and about 1.6 million TB-related deaths in 
20171. Early TB case detection and treatment initiation are 
critical for TB care and global TB elimination.
Sputum smear microscopy remains the primary method for 
diagnosing pulmonary TB in most countries with a high TB 
burden. Microscopy has suboptimal sensitivity and requires 
patients to submit multiple sputum samples often over sev-
eral days, leading to loss to follow-up and missed opportunities 
for case detection and treatment. Nucleic acid amplification 
tests (NAAT) are known to increase sensitivity but until 
recently were not feasible in high-burden countries2. In 20103, 
WHO first recommended Xpert MTB/RIF (Cepheid, Sunny-
vale, CA, USA), a semi-automated, cartridge-based NAAT, as 
a first-line TB test for all patients suspected to have multi-drug 
resistant TB or HIV-associated TB and in 20134, revised the 
recommendation to include Xpert MTB/RIF testing for all 
patients suspected to have TB where resources permit.
Since the initial WHO recommendations based on diagnos-
tic accuracy estimates, several trials5–12 have evaluated whether 
Xpert MTB/RIF testing reduced mortality among those 
undergoing TB evaluation in comparison to smear microscopy 
or pre-existing diagnostic algorithms. These trials have reported 
variable estimates of reduction in mortality, with only two9,11 
reporting a statistically significant decrease in mortality. A 
recently published individual patient data meta-analysis of five 
of such trials6–8,10,13 also did not show significantly reduced 
six-month all-cause mortality (OR 0.88, 95% CI 0.68 to 1.14) 
in adults ≥18 years with presumptive pulmonary TB14.
Available literature cites possible reasons to explain methodo-
logical limitations of test-treatment trials and Xpert MTB/RIF’s 
apparent lack of significant effect on mortality. A meth-
odological review of test-treatment trials (n=103) published 
between 2004 and 2007 concluded that such trials were prob-
ably underpowered and had issues related to blinding, attrition, 
and inadequate primary analyses15. Other reviews of trials of 
Xpert MTB/RIF have raised issues related to the health systems 
in which the trials were conducted16, limited study power14,16, 
persistent use of empirical therapy17, limitations in interpret-
ing trial results by focusing on statistical significance rather than 
clinically important differences18, and enrolling patients whose 
test results are not likely to influence treatment decisions19. 
However, to date, less attention has been paid to the external 
validity of trials: the extent to which the design and 
conduct of the trials reflect what could be expected in usual care. 
In addition to earlier identification of drug resistance, Xpert 
MTB/RIF testing is expected to reduce mortality through 
earlier identification of patients with TB (increased sensitivity 
compared with smear microscopy) and decreased pre-treatment 
loss to follow-up (faster turn-around-time for results). We 
conducted a systematic review to assess whether the design 
and/or execution of studies also contributed to earlier identi-
fication of patients with TB and decreased pre-treatment loss 
to follow-up, thereby reducing the potential impact of Xpert 
MTB/RIF testing.
Methods
Study identification
We conducted a literature search to identify randomised and 
non-randomised studies assessing mortality following the 
introduction of Xpert MTB/RIF testing. We searched the 
Cochrane Central Register of Controlled Trials (CENTRAL), 
MEDLINE, and Scopus for studies in English published between 
1 January 2009 and February 2019 with the terms ‘Xpert MTB/
RIF’ or ‘Xpert’ or ‘GeneXpert’ and ‘impact’ or ‘effect*’ or 
‘implementation’ or ‘trial*’. We included studies that compared 
Xpert MTB/RIF to usual care as defined by the authors (for 
example sputum microscopy or culture), intending to measure 
the effect of these tests on mortality among participants 
presumed to have active pulmonary TB. Hypothetical trials 
or modelling studies were excluded. The study protocol, 
details of which are available as Extended data20, followed 
PRISMA guidelines for performing systematic reviews, where 
applicable21,22; however, since this was not a classical sys-
tematic review, not all items were appropriate. A completed 
checklist is available from Open Science Framework20.
Appraisal of studies
One reviewer (NK) searched, identified and appraised eligi-
ble articles up to December 2016. A second reviewer (EO) 
updated the search, identified and appraised eligible articles 
up to February 2019 in discussion with a senior reviewer 
(AC). The study data were extracted using Google forms and 
included the following elements: general study characteristics 
(geographical location, TB and HIV co-infection); description 
of study arms; sample size and power; description and results 
of the mortality outcome; and description of key study design 
features (study setting and context; study population; participant 
recruitment and enrolment; study procedures and participant 
follow-up). We used descriptive statistics to summarise quan-
titative data and provide a narrative summary of key design 
features concerning their potential impact on usual care. In 
appraising usual care, we considered how the study was 
executed assessing if usual care was enhanced beyond what is 
considered routine23–27.
Results
Characteristics of included studies
Our search yielded 2147 records (Figure 1). From this, eight 
studies were included in this review (Table 1)12. These studies 
comprised three individual randomized trials5,8,10, two clus-
ter randomised trials6,9, one secondary analysis of a stepped 
wedged randomised trial11,13, one cross-over trial7, and one 
pre-post intervention study12. Further information about each trial 
is given as Extended data20.
Each study was described as pragmatic by the study authors 
and involved patients undergoing evaluation for pulmonary 
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TB in routine care settings (primary health care clinics6–11 and 
tertiary referral hospitals5,12). All eight studies were conducted 
in high-TB-burden countries28, including seven in sub-Saharan 
Africa5–10,12, and one in Brazil11. Seven studies included 
adults ≥18 years5–10,12 and one study11 included adults and 
children of any age. Proportion of HIV-positive participants in the 
included studies ranged from 10% to 100%.
Usual care consisted of sputum smear microscopy in all but one 
study, where both culture and smear microscopy comprised 
standard of care5 following a change in government policy 
recommending Xpert MTB/RIF as the initial diagnostic test.
Overall rates of participant loss to follow-up (LTFU) ranged 
from 1% to 22% in included studies. LTFU rates between trial 
arms were similar except for two studies in which LTFU was 
higher in the smear microscopy arm compared to the Xpert 
MTB/RIF arm (10% vs 2%12 and 22% vs 18%8, respectively).
All-cause mortality was evaluated in seven studies5–9,12,17 
and TB-attributed mortality in one study11. Mortality was assessed 
as the primary outcome in three studies6,9,12, as a composite 
primary outcome in one study8 and as a secondary outcome in 
the other four studies5,7,11,17.
All included studies demonstrated relative reductions in over-
all mortality in the Xpert MTB/RIF arm ranging from 6% to 
40%. However, mortality reduction was reported to be sta-
tistically significant in two studies (Table 1)9,11. Ngwira and 
colleagues9 reported a statistically significant reduction in 
all-cause mortality in a subgroup of patients with newly diag-
nosed advanced HIV at primary health clinics in Malawi (RR: 
0.43, 95% CI: 0.22 to 0.87), but not in the overall study population 
(RR: 0.78, 95% CI: 0.58 to 1.06). Trajman and colleagues11 
reported a lower TB-attributed death rate in the Xpert MTB/RIF 
arm (2.3% vs 3.8%; OR: 0.60, 95% CI: 0.42 to 0.86) among 
patients with presumptive TB in primary health clinics in Brazil.
Analysis of key study design features relative to 
usual care
We analysed study features across five domains: study setting 
and context, study population, participant recruitment and enrol-
ment, study procedures, and study follow-up. A summary of 
study features can be found in Table 2.
Figure 1. Flow chart of included studies.
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Table 2. Analysis of study features relative to usual care.
Study Summary of study features
Calligaro et al. (2015)5 Used laboratories that observed high quality standards for TB testing 
Inpatient setting with high pretest probability of TB and empirical treatment 
Informed consent required 
Use of additional testing; culture
Churchyard et al. (2015)6 High quality laboratories used; laboratories not meeting standards excluded 
Patients with reduced chance of LTFU. Excluded patients from remote locations or from outside 
catchment area 
Informed consent required 
Use of additional testing; chest radiographs 
Enhanced follow up by giving airtime vouchers to maintain contact; 
Home visits to those who lost contact
Cox et al. (2014)7 Used laboratories that observed high quality standards for TB testing 
Informed consent waived 
Enhanced follow-up of patients using multiple existing data registries used to follow-up patients; 
Home visits made to test negative patients and test positive patients not on treatment
Mupfumi et al. (2014)8 Used laboratories that observed high quality standards for TB testing 
Population with high likelihood of empirical treatment; HIV positive patients starting ART 
Informed consent required  
Use of additional testing; chest radiographs 
Enhanced follow up by tracking LTFU through clinical records and home visits
Ngwira et al. (2018)9 Used laboratories that observed high quality standards for TB testing 
Population with high likelihood of empirical treatment; HIV positive patients starting ART 
Patients with minimal chance of LTFU. Excluded patients from remote locations or from outside 
catchment area 
Informed consent required 
Continuous training of onsite personnel 
Enhanced follow-up of patients though extra visits, home visits and using data registers
Theron et al. (2014)10 Used laboratories that observed high quality standards for TB testing 
Research staff directly involved in care of participants 
Higher pre-test probability of TB; HIV negative patients required to have ≥ 2 symptoms of TB 
Informed consent required 
Likelihood of increased interaction between study staff and patients through transporting 
patients for additional testing and counselling 
Use of additional testing; chest radiographs and culture
Trajman et al. (2015)11,13 Used laboratories that observed high quality standards for TB testing 
Informed consent waived 
All patients with presumptive TB included; no exclusion criteria 
Utilised routinely collected data from electronic records database 
No additional staff and diagnostics relative to usual care 
No enhanced follow up strategies
Yoon et al. (2012)12 Used laboratories that observed high quality standards for TB testing 
Research staff directly involved in care of participants 
Research staff performed sputum induction and bronchoscopy 
Inpatient setting with high pretest probability of TB and empirical treatment 
Informed consent required 
Likelihood of increased interaction between study staff and patients through transporting 
patients for additional testing and counselling 
Use of additional testing; chest radiographs and culture 
Enhanced follow up by providing transport vouchers and home visits
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Study setting and context
We focused on whether the quality of care in the usual care arm 
was higher at study sites than would be expected in usual care 
settings, either because of the sites chosen or the manner in 
which studies were executed. All eight studies used laborato-
ries that observed high quality standards for TB testing, with one 
study6 excluding laboratories that did not meet quality stand-
ards. In two studies, research staff were directly involved in the 
care of participants, including facilitating chest X-rays, deliv-
ering test results to participants, and referring participants for 
TB treatment10,12. In one study, research staff performed 
sputum induction and bronchoscopy, neither of which were 
routinely available at the study site12.
Study population
Empiric treatment is more common when pre-test probability of 
TB is high17,19 or in study populations with very ill patients who 
have a high likelihood of dying, reducing the potential impact of 
Xpert MTB/RIF, a more sensitive test than sputum microscopy. 
Five studies reported rates of empiric treatment, and the rates 
ranged from 12% to 60%5,8,10–12. Five of eight studies enrolled 
participants with a higher pre-test probability of TB than the tar-
get population (i.e., all patients referred for sputum-based TB 
testing in usual care). Yoon and colleagues12 and Calligaro and 
colleagues5 conducted their studies in inpatient settings, where 
TB prevalence and empiric treatment rates are generally higher 
than in outpatient settings. Theron and colleagues10 required 
HIV-negative participants to have at least two TB symptoms 
(cough for more than two weeks, fever lasting two weeks, weight 
loss, sweats, fatigue, chest pain or hemoptysis), rather than 
enrolling all patients referred for TB testing. Two studies8,9 
included only HIV-positive patients who had not started ART, a 
population in whom empiric treatment is more common. In 
addition to high rates of empiric treatment, Churchyard and 
colleagues6 and Ngwira and colleagues9 excluded patients 
who resided outside the clinic catchment area or in remote 
locations, reducing the potential for loss to follow-up.
Participant recruitment/enrolment
A high level of interaction between research staff and partici-
pants could lead to increased adherence to care and follow-up. 
Study staff requested consent from participants in all but 
two7,11 studies, and as noted earlier, transported patients for 
chest radiographs in two studies10,12. Both studies provided an 
opportunity for research staff to build rapport and counsel and 
educate participants on TB diagnosis and treatment. In addi-
tion, patients were asked to wait for their smear microscopy 
results or were offered voluntary counselling as they were being 
transported for chest radiographs in one study10, likely reducing 
pre-treatment loss to follow-up relative to routine care. 
Study procedures
The use of testing and other procedures not typically available 
in many high burden settings could lead to more patients being 
diagnosed with and treated for TB than would have occurred 
under usual care. For example, chest radiography was performed 
in all participants in two studies10,12, at baseline at the discre-
tion of clinicians in one study8 and in HIV-positive participants 
with a negative index test result in another study6. The avail-
ability of chest radiograph results compatible with active TB is 
likely to have made empiric TB treatment initiation more 
frequent, especially for HIV-positive participants10. Culture is 
not routinely available in most high TB burden settings. How-
ever, it was part of usual care in one study setting5, and was 
performed in two other studies as a reference standard for 
diagnostic test accuracy calculations10,12. In all these three 
studies, a positive culture test result also informed treatment in the 
Xpert MTB/RIF arm.
Study follow-up
To maintain contact and study follow up, Churchyard and 
colleagues6 sent mobile phone call vouchers (worth $2 USD) 
as an incentive to encourage patients to remain contactable 
during the study and later organised home visits when contact 
calling failed. Ngwira and colleagues9 enhanced follow up by 
scheduling extra visits, conducting home visits and using data 
registers to trace participants who missed clinic appointments. 
Yoon and colleagues provided transport vouchers and made home 
visits for patients who did not return for scheduled follow-up 
visits12. The enhanced follow-up procedures likely increased 
initiation of TB treatment for those with bacteriologically- 
confirmed disease and those without bacteriological confirmation 
but persistent symptoms.
Discussion
Our review has implications for the design of future trials 
aiming to assess the comparative effectiveness of novel TB 
diagnostics. We highlight features of trial design and execu-
tion that could have mitigated the key advantages of Xpert 
MTB/RIF relative to smear microscopy with respect to faster 
diagnosis and treatment of TB patients. Such features included: 
a higher quality of care in comparison to usual care at trial 
sites, inclusion of patients with higher pre-test probability of 
TB relative to all patients undergoing TB testing at the trial 
sites leading to higher than expected empiric treatment rates, 
selection criteria and increased contact with participants as a 
result of study procedures leading to reduced pre-treatment loss 
to follow-up, the performance of additional diagnostic test-
ing not done in usual care leading to increased TB diagnosis or 
empiric treatment initiation, the recruitment of partici-
pants likely to return for follow-up, and involvement of 
study staff in ensuring adherence with care. Designing future 
comparative studies of novel TB diagnostics in real life set-
tings where optimal conditions are not likely to be met 
could mitigate these issues and provide a better assessment 
of their likely impact.
Our findings complement those of Auld and colleagues16, who 
also published a literature review exploring Xpert MTB/RIF’s 
lack of effect on morbidity and mortality. They appraised 
eight trials (six randomised5–8,10,11 and two pre-post trials12,29) 
and concluded that study characteristics that may explain this 
lack of effect on morbidity and mortality include underpow-
ered trials, higher rates of empiric treatment in the control arms 
compared to the Xpert MTB/RIF arm, studies with 
populations not comprised exclusively of those likely to 
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benefit from Xpert MTB/RIF, and health system limitations 
such as patient loss to follow-up. Our review extends upon and 
contextualizes these findings by focusing on how specific 
study design and execution features that improve upon usual 
care may mitigate the potential benefit of novel diagnostics.
Of the eight studies included in our review, Trajman and col-
leagues11 minimally interrupted usual care for that setting. 
The study was conducted at public primary care settings, 
included all patients undergoing TB testing (no exclusion cri-
teria) and utilized routinely collected data to assess outcomes. 
Electronic records of routinely collected diagnostic, treatment 
and outcome data were linked and analysed retrospectively 
with minimal influence by external research staff. Trajman and 
colleagues also did not utilize additional resources in terms of 
staff or diagnostics that were used over and above what was 
available in usual care settings and similar implementation pro-
tocols were uniformly applied at all sites. Informed consent 
was also not a requirement.
There is an inherent tension between a study’s internal and 
external validity30,31, with the former favouring more rigorous 
control and the latter more pragmatism. Indeed, most research 
on which practice guidelines have been based have focused 
on internal validity rather than external validity30. For exam-
ple, some selection and/or additional support for study sites is 
needed to ensure the availability of test kits and anti-TB drugs 
during the trial period and some strengthening of routine data 
collection and recording is needed to minimize missing data. 
If a study is completely hands-off with regard to clinical prac-
tice it may not demonstrate effects on mortality because the 
system in which the test is introduced is poorly functioning. 
This may be useful information in that specific context (there 
may be little point in implementing a new diagnostic in the 
context of a dysfunctional health system) but may mislead 
on the potential impact on mortality in a better functioning 
system. In practice, feasibility issues such as available study 
funding and available time to conduct the studies27 mean that 
most studies fall along a continuum between pragmatic 
and explanatory approaches32. In this light, researchers are 
encouraged to use the Pragmatic Explanatory Continuum 
Indicator Summary (PRECIS) tool to inform design deci-
sions on how explanatory (ideal context) or pragmatic (usual 
care context) the study features of their trials can be in 
the pragmatic/explanatory continuum33. Trial findings also need 
to be interpreted in line with the trial’s position in this continuum 
particularly if they are labelled as pragmatic.
When a study aims to provide valid evidence for or against the 
introduction of a trial-validated intervention in real-world set-
tings, a more pragmatic trial is needed to evaluate its performance 
in less controlled, heterogeneous settings and populations 
that are typical of the settings the intervention is intended 
for34. The study population should be all persons that would 
qualify for the intervention under usual care including adults 
and children and participants that may be prone to loss to 
follow-up. Recruitment approaches should be built on existing 
ones35. Individual consent should be inferred from participants’ 
presentation at the health facility and request for treatment 
especially if the intervention under study is already approved. 
Study populations, would, therefore present themselves to 
the health facility staff and be evaluated by no more effort 
than that observed under usual care or alternative methods 
of obtaining consent can be sought such as consent waivers, 
integrated clinical and research consent, and broadcast 
consent (notifications in health settings informing patients 
that trials with minimal risk are permitted)36. The intervention 
should be delivered through usual care providers and resources34. 
Data on patients and outcome measures should also be gath-
ered from routine programmatic data sources wherever 
efforts can be made to strengthen data collection and bring it to 
a higher standard, without having the potentially problematic 
effect of placing research staff at each study site.
The strengths of our review include a comprehensive search 
in multiple databases for studies assessing the effect of Xpert 
MTB/RIF testing on mortality. Two reviewers extracted data 
in discussion with a senior reviewer. Our review was limited 
by focusing on the effect of Xpert MTB/RIF on one health 
outcome. However, other health outcomes such as morbidity and 
quality of life are limited by lack of standardized scores and are 
rarely18 measured in trials. For example, only one trial10 in 
our review evaluated the effect on morbidity and none evalu-
ated the effect on quality of life. An advantage of Xpert is its 
high sensitivity in detecting rifampicin-resistant TB37. It would 
be informative to evaluate the effect of Xpert MTB/RIF on 
health outcomes in patients with rifampicin-resistant TB. How-
ever, none of the included studies evaluated the effect of Xpert 
on rifampicin resistant-TB due to limited prevalence and 
follow-up. In addition, we did not review the effect of Xpert 
testing in children because TB diagnosis in children is still a 
challenge38. Indeed, only one study11 included children. Lastly, 
our review was limited to studies written in English and to what 
was reported in the included studies.
In conclusion, although presented as pragmatic, specific study 
design and execution choices are likely to reduce the ability of 
trials to demonstrate an impact of Xpert MTB/RIF testing on 
mortality. Offering higher quality of care than what occurs in 
usual care may lead to differences in mortality between con-
trol and intervention arms that are smaller than would have 
been observed with usual care. Trialists face an inherent 
tension between balancing internal and external validity. 
Nonetheless, our findings indicate trials that are further along 
the explanatory-pragmatic continuum are needed to evaluate the 
impact of the next-generation of TB diagnostics in real-world 
settings.
Data availability
Underlying data
All data underlying the results are available as part of the 
article and no additional source data are required.
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Extended data
Open Science Framework: Variation in the observed effect 
of Xpert MTB/RIF testing for tuberculosis on mortality. 
https://doi.org/10.17605/OSF.IO/HXYQW20.
This project contains the following extended data:
•    Protocol-Literature Review_v4 (protocol for this review).
•    Systematic review data-TB Xpert Effect (data on 
studies identified by this review).
Reporting guidelines
Open Science Framework: PRISMA checklist and flow chart 
for ‘Variation in observed effect of Xpert MTB/RIF testing 
for tuberculosis on mortality’ https://doi.org/10.17605/OSF.IO/
HXYQW20.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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Thank you for the opportunity to review this systematic review and analysis of trial design considerations
in the evaluation of Xpert MTB/RIF.
When Xpert MTB/RIF was first reported to have much higher sensitivity than the current test (smear
microscopy), it was widely assumed to be a game changer in terms of TB diagnostics. Multiple clinical
trials along with meta-analyses have shown that the impact is much less than was anticipated.
Rather than accept that Xpert MTB/RIF might not be an important addition to TB diagnostics, multiple
authors have tried to explain the lack of trial efficacy by examining the trial design.
In this review, the authors focus on 5 areas, study setting and context, population, recruitment and
enrollment, study procedures and follow-up.  
The authors make a strong argument for many of the studies having sub-optimal design in these aspects
and conclude that “trialists face an inherent tension between balancing internal and external validity.
Nonetheless, our findings indicate trials that are further along the explanatory-pragmatic continuum are
needed to evaluate the impact of the next-generation of TB diagnostics in real-world settings.”
This is an interesting argument as in general, when trials are less pragmatic there tends to be a larger
effect size than in real world settings. The authors are arguing that in this instance, the opposite is true,
and that larger effect sizes would be seen in real world settings.
Their arguments are convincing but do not address the main reasons for the failure of these studies to
show an effect on mortality. In this reviewer’s opinion, the primary reason that many of these trials failed to
show an effect of Xpert MTB/RIF was fundamental design flaws in terms of the choice of the intervention
arm.
The fundamentals of determining the impact of a novel diagnostic is to perform ‘test research’ (diagnostic
accuracy studies) before moving to ‘diagnostic research’ (e.g. developing algorithms or prediction rules),
1
2
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 accuracy studies) before moving to ‘diagnostic research’ (e.g. developing algorithms or prediction rules),
before finally moving to ‘diagnostic intervention research’ (randomised trials). In the case of Xpert
MTB/RIF no adequate ‘diagnostic research’ was performed and so appropriate diagnostic strategies were
not developed prior to designing randomised trials. The trials therefore merely tested the standard of care,
which was smear microscopy and frequent empiric therapy (due to the known lack of sensitivity of smear)
vs Xpert MTB/RIF as a stand alone test. An appropriate research strategy would have been to first
develop a full diagnostic strategy based around Xpert MTB/RIF, which included for example, therapy for
patients with a high pre-test probability of disease regardless of Xpert result, empiric therapy for patients
with high pre-test probability who were unable to produce sputum, possibly with the inclusion of a trial of
antibiotics and referral for CXR when the diagnosis was in doubt.
Such an approach would have adequately compared the current standard of care with an evidence based
diagnostic strategy which included Xpert MTB/RIF. In their form that these studies were done, it was in my
opinion highly likely that no effect would be seen.
Therefore, while the authors make some convincing arguments as to how these trials might have been
better designed, my suggestion would be that they acknowledge that these were minor flaws in
comparison to those mentioned above. I would conclude that while there is room for improvement in the 5
areas they discuss, adequate randomised trials of Xpert MTB/RIF would compare the current standard of
care diagnostic strategy based around smear microscopy. with a novel diagnostic strategy which included
Xpert MTB/RIF, rather than simply comparing a test with another test.
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